Sign In
Buy ALKS
$42.76
+1.44 (+3.48%)
At Close: Jun 03, 2026
Alkermes plc (ALKS) Q3 2025 Earnings Call Transcript
03:21pm, Tuesday, 28'th Oct 2025
Alkermes plc (NASDAQ:ALKS ) Q3 2025 Earnings Call October 28, 2025 8:00 AM EDT Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Richard F. Pops - Ch
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
12:00pm, Tuesday, 28'th Oct 2025
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street est
Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates
09:21am, Tuesday, 28'th Oct 2025
Alkermes (ALKS) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.73 per share a year ago.
Alkermes plc Reports Third Quarter 2025 Financial Results
07:00am, Tuesday, 28'th Oct 2025
— Third Quarter Revenues of $394.2 Million — — GAAP Net Income of $82.8 Million and Diluted GAAP Earnings per Share of $0.49 — — Company Raises 2025 Financial Expectations
Allspring Global Investments Holdings LLC Reduces Holdings in Alkermes plc $ALKS
03:46am, Friday, 24'th Oct 2025
Allspring Global Investments Holdings LLC reduced its holdings in shares of Alkermes plc (NASDAQ: ALKS) by 70.8% in the undefined quarter, according to its most recent 13F filing with the Securities a
Critical Survey: Alkermes (NASDAQ:ALKS) and Structure Therapeutics (NASDAQ:GPCR)
02:42am, Friday, 24'th Oct 2025
Alkermes (NASDAQ: ALKS - Get Free Report) and Structure Therapeutics (NASDAQ: GPCR - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies base
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition
11:30am, Thursday, 23'rd Oct 2025
Alkermes inks $2.1B deal to acquire Avadel, adding the latter's Lumryz and new growth potential to its portfolio.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz
03:18pm, Wednesday, 22'nd Oct 2025
On Wednesday, Alkermes plc (NASDAQ:ALKS) agreed to acquire Avadel Pharmaceuticals plc (NASDAQ:AVDL) for up to $20 per share in cash, which values Avadel at approximately $2.1 billion.
Alkermes plc (ALKS) M&A Call Transcript
10:53am, Wednesday, 22'nd Oct 2025
Alkermes plc (NASDAQ:ALKS ) M&A Call October 22, 2025 8:00 AM EDT Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Richard F. Pops - Chairman & CEO
Avadel Jumps On $2.1 Billion Takeover Deal. But Buyer, Alkermes, Dives.
09:33am, Wednesday, 22'nd Oct 2025
Shares of Alkermes and Avadel Pharmaceuticals diverged Wednesday after the former agreed to buy the latter for up to $2.1 billion.
Alkermes to acquire Avadel for up to $2.1 billion
07:11am, Wednesday, 22'nd Oct 2025
Alkermes said on Wednesday it will acquire Avadel Pharmaceuticals for up to $2.1 billion gaining access to the company's approved excessive daytime sleepiness drug.
Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
07:00am, Wednesday, 22'nd Oct 2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIO
ALKS vs. RGEN: Which Stock Is the Better Value Option?
12:41pm, Tuesday, 21'st Oct 2025
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Alkermes (ALKS) or Repligen (RGEN). But which of these two stocks offers value investors a be
Wall Street Analysts Predict a 34.8% Upside in Alkermes (ALKS): Here's What You Should Know
10:56am, Tuesday, 21'st Oct 2025
The mean of analysts' price targets for Alkermes (ALKS) points to a 34.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
